Triazole-Based Compound as a Candidate To Develop Novel Medicines To Treat Toxoplasmosis
| dc.contributor.author | Dzitko, Katarzyna | |
| dc.contributor.author | Paneth, Agata | |
| dc.contributor.author | Plech, Tomasz | |
| dc.contributor.author | Pawełczyk, Jakub | |
| dc.contributor.author | Węglińska, Lidia | |
| dc.contributor.author | Paneth, Piotr | |
| dc.date.accessioned | 2016-02-09T07:34:21Z | |
| dc.date.available | 2016-02-09T07:34:21Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | This article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis. | en_EN |
| dc.identifier.citation | Antimicrobial Agents and Chemotherapy, Vol. 58, Issue 12, pages 7583-7585 | |
| dc.identifier.uri | http://hdl.handle.net/11652/1149 | |
| dc.identifier.uri | http://aac.asm.org/content/58/12/7583.full.pdf+html | |
| dc.language.iso | en | en_EN |
| dc.relation.ispartofseries | Antimicrobial Agents and Chemotherapy, Vol. 58, Issue 12, 2014 | en_EN |
| dc.title | Triazole-Based Compound as a Candidate To Develop Novel Medicines To Treat Toxoplasmosis | en_EN |
| dc.type | Artykuł | pl_PL |
| dc.type | Article | en_EN |